Table 6: Frequency of CNR1 polymorphisms in study and control groups.

A3813G (rs12720071) (chi2) A4895G (rs806368) (chi2)
A/AA/GG/GT/TC/TC/C

PCOS + NAFLD64.41% (38)68.42% (13)50% (13)0.35 (2.04)58.82% (40)57.69% (15)87.5% (7)0.27 (2.6)
PCOS − NAFLD35.59% (21)31.58% (6)50% (13)41.18% (28)42.31% (11)12.5% (1)
Control + NAFLD48.48% (32)28.57% (4)66.67% (4)0.24 (2.89)46.3% (25)46.88% (15)100% (1)0.57 (1.14)
Control − NAFLD51.52% (34)71.43% (10)33.33% (2)53.7% (29)53.13% (17)0.00% (0)

G1422A (rs1049353) (chi2) rs806381 (chi2)
A/AG/AG/GA/AG/AG/G

PCOS + NAFLD48% (12)69.7% (23)64.58% (31)0.21 (3.05)72% (18)37.5% (9)66.67% (28)0.025 (7.36)
PCOS − NAFLD52% (13)30.3% (10)35.42% (17)28% (7)62.5% (15)33.33% (14)
Control + NAFLD33.33% (4)50% (14)48.98% (24)0.58 (1.07)45% (18)50% (21)44.44% (8)0.88 (0.26)
Control − NAFLD66.67% (8)50% (14)51.02% (25)55% (22)50% (21)55.56% (10)

rs10485170 (chi2)rs6454674 (chi2)
A/AA/GG/GT/TG/TG/G

PCOS + NAFLD61.9% (52)45.45% (5)75% (6)0.03 (7.04)69.39% (34)48.89% (22)76.92% (10)0.06 (5.62)
PCOS − NAFLD38.1% (32)54.55% (6)25% (2)30.61% (15)51.11% (23)23.08% (3)
Control + NAFLD50% (41)42.86% (9)0%0.56 (0.34)48.98% (24)50% (20)42.86% (6)0.89 (0.22)
Control − NAFLD50% (41)57.14% (12)0%51.02% (25)50% (20)57.14% (8)

PCOS + NAFLD: women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
PCOS − NAFLD: women with polycystic ovary syndrome without nonalcoholic fatty liver disease.
Control + NAFLD: women from control group having nonalcoholic fatty liver disease.
Control − NAFLD: women from control group without nonalcoholic fatty liver disease.